Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1

Conditions

Recurrence 1Mesothelioma, Malignant 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Specimen Handling 439Magnetic Resonance Spectroscopy 341pembrolizumab 288Biopsy 241Carboplatin 230Cisplatin 193Cyclophosphamide 185Paclitaxel 164Nivolumab 153Gemcitabine 151Bevacizumab 121Radiotherapy 119Dexamethasone 113fludarabine 99Pemetrexed 99Fluorouracil 94durvalumab 90Doxorubicin 90venetoclax 89Docetaxel 89Radiation 88Oxaliplatin 88Rituximab 87atezolizumab 84Leucovorin 79Capecitabine 75Prednisone 74Lenalidomide 69Etoposide 69X-Rays 65

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Combined Modality Therapy × 30 days × Clear all
NCT06251310 2026-05-08

SW-682 in Advanced Solid Tumors

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Recruiting
186 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡